Akouos (AKUS) USPTO patents

Utility

Compositions and Methods of Inducing Differentiation of a Hair Cell

15 Dec 22

Provided herein are compositions that include one or more adeno-associated virus (AAVs) vectors and methods of inducing differentiation of a hair cell using these vector(s).

Emmanuel John Simons, Robert Ng, Danielle R. Lenz, Michelle Valero

Filed: 7 Nov 19

Utility

Methods of Treating Hearing Loss Using a Secreted Target Protein

15 Dec 22

Provided herein are compositions that include a single nucleic acid vector or two different nucleic acid vectors, and the use of these compositions to treat hearing loss in a subject.

Emmanuel J. Simons, Robert Ng, Danielle R. Lenz, Hao Chiang

Filed: 24 Jul 20

Utility

Compositions and methods for treating non-age-associated hearing impairment in a human subject

13 Dec 22

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Emmanuel John Simons, Ellen Reisinger, Sebastian Kügler, Hanan Al-Moyed

Filed: 16 Jul 21

Utility

Aav-mediated Delivery of Therapeutic Antibodies to the Inner Ear

25 Aug 22

Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Emmanuel John Simons, Robert Ng, Michael McKenna

Filed: 17 Mar 22

Utility

Compositions and Methods for Treating Non-age-associated Hearing Impairment In a Human Subject

10 Feb 22

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Emmanuel John Simons, Robert Ng, Ellen Reisinger, Hanan Al-Moyed, Sebastian Kügler

Filed: 8 Apr 21

Utility

a Method for Treating an Auditory Neuropathy Spectrum Disorder

6 Jan 22

The present invention provides a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring the gene of DFNB59 via an adeno-associated virus (AAV) vector to the subject.

Yen-Fu Cheng, Chen-Chi Wu, Ying-Chang Lu

Filed: 27 Sep 19

Utility

Aav-mediated Delivery of Therapeutic Antibodies to the Inner Ear

25 Nov 21

Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Emmanuel John Simons, Robert Ng, Michael McKenna

Filed: 3 Aug 21

Utility

Compositions and Methods for Treating Non-age-associated Hearing Impairment In a Human Subject

25 Nov 21

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Emmanuel John Simons, Ellen Reisinger, Sebastian Kügler, Hanan Al-Moyed

Filed: 16 Jul 21

Utility

Methods of Treating Non-syndromic Sensorineural Hearing Loss

28 Oct 21

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of a stereocilin protein, and the use of these compositions to treat non-syndromic sensorineural hearing loss in a subject.

Emmanuel John Simons, Robert Ng

Filed: 12 Jul 19

Utility

Methods of Treating CLRN1-ASSOCIATED Hearing Loss And/or Vision Loss

9 Sep 21

Provided herein are compositions that include a single nucleic acid vector or two different nucleic acid vectors, and the use of these compositions to treat hearing loss and/or vision loss in a subject.

Emmanuel John Simons, Robert Ng

Filed: 25 Jun 19

Utility

Aav-mediated Delivery of Therapeutic Antibodies to the Inner Ear

11 Mar 21

Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Emmanuel John Simons, Robert Ng, Michael McKenna

Filed: 19 Dec 18

Utility

Compositions and Methods for Treating Non-age-associated Hearing Impairment In a Human Subject

16 Dec 20

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Emmanuel John Simons, Robert Ng, Ellen Reisinger, Hanan Al-Moyed, Sebastian Kügler

Filed: 21 Feb 19